These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25729821)

  • 1. No compelling reason to adopt new antivirals whenever it is reasonable to wait.
    Prescrire Int; 2015 Jan; 24(156):8. PubMed ID: 25729821
    [No Abstract]   [Full Text] [Related]  

  • 2. Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
    Prescrire Int; 2015 Jan; 24(156):5-10. PubMed ID: 25734194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis C virus infection in the near future.
    Cheinquer H
    Ann Hepatol; 2013; 12(6):854-9. PubMed ID: 24114813
    [No Abstract]   [Full Text] [Related]  

  • 4. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV treatment--no more room for interferonologists?
    Drenth JP
    N Engl J Med; 2013 May; 368(20):1931-2. PubMed ID: 23607592
    [No Abstract]   [Full Text] [Related]  

  • 6. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
    Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
    N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.
    Asselah T
    J Hepatol; 2014 Aug; 61(2):435-8. PubMed ID: 24816173
    [No Abstract]   [Full Text] [Related]  

  • 8. Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
    Graf Einsiedel H; Christiansen H; Wiegand J
    Pediatr Infect Dis J; 2016 Dec; 35(12):1373. PubMed ID: 27832030
    [No Abstract]   [Full Text] [Related]  

  • 9. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
    Koff RS
    Aliment Pharmacol Ther; 2014 Mar; 39(5):478-87. PubMed ID: 24387618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
    Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Subramanian GM; Symonds WT; McHutchison JG; Pang PS
    Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3.
    Bari K; Sharma P
    Gastroenterology; 2014 Aug; 147(2):534-6. PubMed ID: 24953626
    [No Abstract]   [Full Text] [Related]  

  • 12. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.
    Hussar DA; Kavelak HL
    J Am Pharm Assoc (2003); 2015; 55(2):216, 219-20, 222. PubMed ID: 25749267
    [No Abstract]   [Full Text] [Related]  

  • 13. Daclatasvir plus sofosbuvir for HCV infection.
    Sulkowski MS; Jacobson IM; Nelson DR
    N Engl J Med; 2014 Apr; 370(16):1560-1. PubMed ID: 24738674
    [No Abstract]   [Full Text] [Related]  

  • 14. Daclatasvir plus sofosbuvir for HCV infection.
    Dhaliwal HS; Nampoothiri RV
    N Engl J Med; 2014 Apr; 370(16):1560. PubMed ID: 24738675
    [No Abstract]   [Full Text] [Related]  

  • 15. Sofosbuvir (Sovaldi) for the treatment of hepatitis C.
    Lam B; Henry L; Younossi Z
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):555-66. PubMed ID: 24918162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy.
    Messori A; Maratea D; Fadda V; Trippoli S
    Aliment Pharmacol Ther; 2014 Jul; 40(2):217-8. PubMed ID: 24946068
    [No Abstract]   [Full Text] [Related]  

  • 17. The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.
    Guedj J; Dahari H; Uprichard SL; Perelson AS
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):397-9. PubMed ID: 23899277
    [No Abstract]   [Full Text] [Related]  

  • 18. Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection.
    Nehra V; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2017 Mar; 53(3):177-189. PubMed ID: 28447075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter: calcineurin inhibitor level reduction during treatment with sofosbuvir in liver transplanted patients.
    Vukotic R; Morelli MC; Pinna AD; Margotti M; Foschi FG; Loggi E; Bernardi M; Andreone P
    Aliment Pharmacol Ther; 2014 Aug; 40(4):405. PubMed ID: 25040927
    [No Abstract]   [Full Text] [Related]  

  • 20. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
    Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Symonds WT; Hindes RG; Berrey MM
    N Engl J Med; 2013 Jan; 368(1):34-44. PubMed ID: 23281974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.